Arie S. Belldegrun is an entrepreneur and businessperson who founded 6 companies, among them: Kite Pharma, Inc., Allogene Therapeutics, Inc. and Agensys, Inc. and who has been the head of 16 different companies. Presently, Dr. Belldegrun is Co-Chairman at Breakthrough Properties LLC, Chairman of Kronos Bio, Inc., Chairman & Partner at Two River Group Holdings LLC, Executive Chairman of Allogene Therapeutics, Inc. (which he founded in 2017), Chairman of Two River Group Management LLC, Chairman for Bellco Capital LLC (which he founded in 2003), Chairman & Partner at Two River Consulting LLC, Chairman of Two Rivers Consulting Corp., Chairman at UroGen Pharma Ltd., Senior Managing Director at VV Manager LLC (which he founded in 2017), Senior Managing Director at Vida Ventures LLC (which he founded in 2017) (a subsidiary of VV Manager LLC) and Chairman for Technology Assessment Group. Arie S. Belldegrun is also Head-Urologic Oncology Division at David Geffen School of Medicine, Senior Managing Director at Vida Ventures LLC (he founded the company in 2017) and Director & Professor at UCLA Institute of Urologic Oncology and on the board of 5 other companies.
In the past he was Chairman of Arno Therapeutics, Inc. and Non-Executive Chairman at Arno Therapeutics, Inc. (a subsidiary of Arno Therapeutics, Inc.), Chairman, President & Chief Executive Officer of Equinor ASA, Executive Chairman, President & CEO at Kite Pharma, Inc. (he founded the company in 2009), Director at Agensys, Inc. (he founded the company in 1997), Chairman-Molecular Biological Technology Committee at American Urological Association Education & Research, Inc., Researcher at National Cancer Institute and Member of Los Angeles Economy & Jobs Committee.
Arie S. Belldegrun received a doctorate from The Hebrew University Hadassah Medical School and a graduate degree from Weizmann Institute of Science.